Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Twelve GLP-1 receptor agonists have received FDA approval since 2005, with eight currently available in the United States as of April 2026
- The category splits into single-receptor GLP-1 agonists (exenatide, liraglutide, semaglutide, dulaglutide, lixisenatide) and dual-receptor GLP-1/GIP agonists (tirzepatide), with distinct efficacy profiles
- Delivery methods range from twice-daily injections to once-weekly formulations and one oral tablet, with absorption rates and side effect profiles varying significantly by route
- Compounded versions of semaglutide and tirzepatide became widely available during the 2023-2026 FDA shortage period, offering cost-accessible alternatives to brand-name products for patients meeting clinical criteria
Direct answer (40-60 words)
The FDA has approved twelve GLP-1 receptor agonists since 2005. Eight remain available in 2026: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide extended-release (Bydureon BCise), and lixisenatide (Adlyxin). Four have been discontinued. Compounded semaglutide and tirzepatide are available during ongoing shortages.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The current FDA-approved GLP-1 agonist drugs
- How GLP-1 drugs are classified by receptor target
- Single-receptor GLP-1 agonists: the complete list
- Dual-receptor GLP-1/GIP agonists: tirzepatide and future options
- Discontinued GLP-1 drugs and why they left the market
- Compounded GLP-1 medications: legal status and availability
- Delivery methods: daily vs weekly injections vs oral formulations
- The efficacy hierarchy: which drugs produce the most weight loss
- What most articles get wrong about "GLP-1 drugs"
- How to choose between GLP-1 options: the decision framework
- Triple agonists and next-generation drugs in development
- FAQ
- Sources
The current FDA-approved GLP-1 agonist drugs
As of April 2026, eight GLP-1 receptor agonists hold active FDA approval and remain commercially available in the United States:
| Drug name (generic) | Brand name(s) | Approved indication(s) | Dosing frequency | FDA approval year |
|---|---|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes | Weekly injection | 2017 |
| Semaglutide | Wegovy | Obesity | Weekly injection | 2021 |
| Semaglutide | Rybelsus | Type 2 diabetes | Daily oral tablet | 2019 |
| Tirzepatide | Mounjaro | Type 2 diabetes | Weekly injection | 2022 |
| Tirzepatide | Zepbound | Obesity | Weekly injection | 2023 |
| Dulaglutide | Trulicity | Type 2 diabetes | Weekly injection | 2014 |
| Liraglutide | Victoza | Type 2 diabetes | Daily injection | 2010 |
| Liraglutide | Saxenda | Obesity | Daily injection | 2014 |
| Exenatide ER | Bydureon BCise | Type 2 diabetes | Weekly injection | 2012 (reformulated 2017) |
| Lixisenatide | Adlyxin | Type 2 diabetes | Daily injection | 2016 |
The table shows a pattern: most drugs receive separate brand names for diabetes vs obesity indications despite containing identical active ingredients. Semaglutide and tirzepatide follow this model. Liraglutide does as well. The distinction is regulatory and marketing-driven, not pharmacological.
How GLP-1 drugs are classified by receptor target
The term "GLP-1 drug" is technically imprecise. The category contains two mechanistically distinct drug classes:
Single-receptor GLP-1 agonists bind exclusively to the GLP-1 receptor. This includes exenatide, liraglutide, semaglutide, dulaglutide, and lixisenatide. These drugs mimic the action of endogenous GLP-1, a gut hormone that stimulates insulin secretion, slows gastric emptying, and reduces appetite.
Dual-receptor GLP-1/GIP agonists bind both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Tirzepatide is currently the only FDA-approved drug in this category. GIP activation appears to enhance insulin secretion and improve lipid metabolism beyond what GLP-1 activation achieves alone.
The clinical difference is meaningful. In head-to-head trials, tirzepatide produces 15% to 22% total body weight loss at maintenance doses, compared to 10% to 15% for semaglutide 2.4 mg (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). The dual-receptor mechanism explains most of that gap.
A third category is emerging: triple-receptor agonists that add glucagon receptor activation to GLP-1 and GIP. Retatrutide is the lead candidate, currently in phase 3 trials. Early data shows 24% weight loss at 48 weeks (Jastreboff et al., NEJM 2023). These drugs will likely join the FDA-approved list between 2027 and 2029.
For practical purposes, when patients ask "which GLP-1 drug," they usually mean "which incretin-based medication," which includes both single and dual-receptor options. The distinction matters for understanding efficacy differences.
Single-receptor GLP-1 agonists: the complete list
Exenatide (Byetta, Bydureon BCise)
Exenatide was the first GLP-1 agonist approved by the FDA in 2005. It's a synthetic version of exendin-4, a peptide found in Gila monster saliva. The original formulation (Byetta) required twice-daily injections and is now discontinued in the U.S. The extended-release version (Bydureon BCise) delivers once-weekly dosing via microsphere suspension technology.
Exenatide produces modest weight loss (2 to 3 kg on average) and A1C reductions of 0.8% to 1.5% (Buse et al., Lancet 2004). It's rarely prescribed as a first-line option in 2026 because newer agents offer better efficacy and simpler dosing.
Dosing: Bydureon BCise 2 mg once weekly, subcutaneous injection.
Liraglutide (Victoza, Saxenda)
Liraglutide is a once-daily GLP-1 agonist approved for diabetes (Victoza, 2010) and obesity (Saxenda, 2014). It has a 97% structural similarity to human GLP-1 with a fatty acid side chain that extends half-life to approximately 13 hours.
Liraglutide 3.0 mg (Saxenda) produces 5% to 8% total body weight loss over 56 weeks in obesity trials (Pi-Sunyer et al., NEJM 2015). The diabetes formulation (Victoza, max 1.8 mg daily) produces 2 to 3 kg weight loss as a secondary benefit.
The daily injection requirement is the main drawback compared to weekly semaglutide. Nausea rates are comparable. Liraglutide remains a reasonable option for patients who prefer daily dosing or who have insurance coverage issues with newer agents.
Dosing: Victoza 0.6 mg to 1.8 mg daily; Saxenda 0.6 mg titrated to 3.0 mg daily, subcutaneous injection.
Semaglutide (Ozempic, Wegovy, Rybelsus)
Semaglutide is a modified GLP-1 analog with 94% homology to human GLP-1. Structural modifications extend half-life to approximately 7 days, enabling once-weekly dosing. It's available as a subcutaneous injection (Ozempic for diabetes, Wegovy for obesity) and as an oral tablet (Rybelsus for diabetes).
Semaglutide 2.4 mg produces 10% to 15% total body weight loss over 68 weeks in the STEP trial program (Wilding et al., NEJM 2021). A1C reductions range from 1.5% to 2.0% in diabetes trials (Sorli et al., Lancet Diabetes Endocrinol 2017).
Semaglutide became the most-prescribed GLP-1 drug in the U.S. between 2021 and 2024, driving widespread shortages that triggered FDA addition to the shortage list in March 2022 (still active as of April 2026).
Dosing: Ozempic 0.25 mg to 2.0 mg weekly; Wegovy 0.25 mg titrated to 2.4 mg weekly; Rybelsus 3 mg to 14 mg daily oral.
Dulaglutide (Trulicity)
Dulaglutide is a fusion protein linking two GLP-1 analog molecules to an IgG4 Fc fragment, extending half-life to approximately 5 days. Approved in 2014, it's available only for type 2 diabetes, not obesity.
Dulaglutide 1.5 mg produces A1C reductions of 1.1% to 1.6% and weight loss of 2 to 3 kg (Wysham et al., Diabetes Care 2014). The 4.5 mg dose, approved in 2020, produces slightly better outcomes but remains less effective than semaglutide or tirzepatide for weight loss.
Trulicity uses a single-use pen with a hidden needle, which some patients prefer over visible-needle devices.
Dosing: 0.75 mg to 4.5 mg once weekly, subcutaneous injection.
Lixisenatide (Adlyxin)
Lixisenatide is a once-daily GLP-1 agonist approved in 2016 for type 2 diabetes. It's structurally similar to exenatide with modifications that extend duration of action to 24 hours.
Lixisenatide produces A1C reductions of 0.7% to 0.9% and minimal weight loss (1 to 2 kg) compared to other GLP-1 drugs (Rosenstock et al., Diabetes Care 2010). It's the least prescribed GLP-1 agonist in the U.S. as of 2026, primarily due to lower efficacy and daily dosing requirement.
Dosing: 10 mcg daily for 14 days, then 20 mcg daily, subcutaneous injection.
Dual-receptor GLP-1/GIP agonists: tirzepatide and future options
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide is the first and only FDA-approved dual GLP-1/GIP receptor agonist. It activates GLP-1 receptors with similar potency to semaglutide while also activating GIP receptors, which enhances insulin secretion, improves lipid metabolism, and may have direct effects on adipose tissue.
The SURMOUNT-1 trial showed 15% to 22.5% total body weight loss at 72 weeks depending on dose (Jastreboff et al., NEJM 2022). The SURPASS trial program in diabetes showed A1C reductions of 1.9% to 2.5%, superior to semaglutide 1.0 mg in head-to-head comparison (Frías et al., NEJM 2021).
Tirzepatide's side effect profile is similar to semaglutide: nausea (20% to 30%), diarrhea (15% to 20%), and constipation (10% to 15%) during titration. Gastric emptying delay is comparable.
Dosing: Mounjaro 2.5 mg titrated to 15 mg weekly; Zepbound 2.5 mg titrated to 15 mg weekly, subcutaneous injection.
Future dual and triple agonists
Several next-generation incretin drugs are in late-stage development:
Retatrutide (triple GLP-1/GIP/glucagon agonist): Phase 3 trials ongoing. Produces 24% weight loss at 48 weeks, the highest efficacy of any obesity medication tested to date (Jastreboff et al., NEJM 2023). Expected FDA submission 2026-2027.
Survodutide (dual GLP-1/glucagon agonist): Phase 2 data shows 12% to 15% weight loss. Glucagon activation increases energy expenditure, potentially addressing metabolic adaptation that limits weight loss with GLP-1-only drugs.
Mazdutide (dual GLP-1/glucagon agonist): Similar mechanism to survodutide, currently in phase 2 trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
The trend is clear: polypharmacology targeting multiple incretin and metabolic hormone receptors produces superior weight loss compared to GLP-1 activation alone.
Discontinued GLP-1 drugs and why they left the market
Four FDA-approved GLP-1 drugs have been discontinued in the United States:
Exenatide immediate-release (Byetta): Discontinued 2020. Twice-daily dosing became obsolete when weekly formulations entered the market. No safety issues drove the discontinuation.
Albiglutide (Tanzeum): Approved 2014, discontinued 2018. Weekly injection, but required reconstitution from powder, which patients found cumbersome. Market share never exceeded 2%. GSK cited commercial reasons for withdrawal, not safety concerns.
Semaglutide oral 7 mg (Rybelsus): The 7 mg tablet strength was discontinued in 2024 when the 14 mg strength became available. Patients previously on 7 mg were transitioned to 14 mg for better efficacy.
Liraglutide/insulin degludec combination (Xultophy): Technically still approved but effectively unavailable due to manufacturing issues since 2023. The combination product offered convenience for patients needing both basal insulin and GLP-1 therapy but never gained significant market share.
The pattern across discontinuations: inconvenient dosing or formulation issues, not safety signals. No GLP-1 drug has been withdrawn for adverse events.
Compounded GLP-1 medications: legal status and availability
Compounded semaglutide and tirzepatide became widely available starting in 2023 when both drugs appeared on the FDA shortage list. Under federal law (Section 503A of the FD&C Act), compounding pharmacies may prepare copies of commercially available drugs during shortages if the pharmacy holds appropriate state licenses and the medication is prescribed for an individual patient.
Legal framework: Compounded GLP-1 drugs are not FDA-approved. They have not undergone the same safety and efficacy review as brand-name products. The FDA permits compounding during shortages but does not verify quality, potency, or sterility of individual compounded batches. State boards of pharmacy regulate compounding facilities.
Current availability (April 2026): Both semaglutide and tirzepatide remain on the FDA shortage list. Compounded versions are legally available through licensed compounding pharmacies with valid prescriptions. Most compounded formulations are supplied as lyophilized powder requiring reconstitution, though some pharmacies offer pre-mixed solutions.
Cost difference: Compounded semaglutide typically costs $200 to $400 per month compared to $900 to $1,300 for brand-name Wegovy or Ozempic without insurance. Compounded tirzepatide costs $300 to $500 per month vs $1,000 to $1,400 for Mounjaro or Zepbound.
Quality considerations: Compounded medications vary in quality. Reputable compounding pharmacies follow USP 797 sterile compounding standards and provide certificates of analysis showing potency testing. Patients should verify their pharmacy is licensed in their state and uses FDA-registered facilities.
FormBlends works exclusively with compounding pharmacies that meet or exceed USP 797 standards and provide third-party potency verification for every batch.
Delivery methods: daily vs weekly injections vs oral formulations
GLP-1 drugs use three delivery methods, each with distinct pharmacokinetic profiles and patient experience:
Daily subcutaneous injections
Liraglutide, lixisenatide, and exenatide immediate-release (discontinued) require daily injections. The shorter half-life means more frequent dosing but also faster washout if side effects become intolerable.
Advantages: Easier dose adjustment, faster side effect resolution if medication is stopped, lower peak drug concentration (potentially fewer GI side effects for some patients).
Disadvantages: Daily injection burden, higher cumulative injection site reaction risk, requires consistent daily routine.
Weekly subcutaneous injections
Semaglutide, tirzepatide, dulaglutide, and exenatide ER use once-weekly dosing. Extended half-life (5 to 7 days) maintains therapeutic drug levels between doses.
Advantages: Convenience, better adherence rates (75% to 85% vs 60% to 70% for daily injections per real-world data), fewer total injections.
Disadvantages: Side effects persist longer if they occur, slower dose adjustment, 5 to 7 day washout period if discontinuation is needed.
Oral tablets
Rybelsus (oral semaglutide) is the only oral GLP-1 formulation. It uses a permeation enhancer (SNAC) to facilitate GI absorption of the peptide, which normally degrades in stomach acid.
Absorption requirements: Must be taken on empty stomach with no more than 4 ounces of water, then no food or drink for 30 minutes. These restrictions reduce real-world adherence.
Bioavailability: Oral semaglutide has approximately 1% bioavailability compared to subcutaneous formulation. The 14 mg oral tablet delivers roughly equivalent systemic exposure to 0.5 mg subcutaneous injection.
Efficacy: Oral semaglutide produces 5% to 7% weight loss and A1C reductions of 1.0% to 1.5%, lower than injectable semaglutide 2.4 mg (Aroda et al., Lancet 2019). Many patients prefer injections once they understand the efficacy difference.
The efficacy hierarchy: which drugs produce the most weight loss
Published trial data establishes a clear efficacy hierarchy for weight loss:
| Drug | Dose | Mean weight loss at 1 year | Trial | Year |
|---|---|---|---|---|
| Tirzepatide | 15 mg weekly | 22.5% | SURMOUNT-1 | 2022 |
| Tirzepatide | 10 mg weekly | 19.5% | SURMOUNT-1 | 2022 |
| Semaglutide | 2.4 mg weekly | 14.9% | STEP 1 | 2021 |
| Tirzepatide | 5 mg weekly | 15.0% | SURMOUNT-1 | 2022 |
| Semaglutide | 1.0 mg weekly | 9.6% | STEP 2 | 2021 |
| Liraglutide | 3.0 mg daily | 8.0% | SCALE | 2015 |
| Dulaglutide | 4.5 mg weekly | 4.7% | AWARD-11 | 2020 |
| Semaglutide oral | 14 mg daily | 6.9% | PIONEER 1 | 2019 |
The pattern: tirzepatide produces the most weight loss, followed by injectable semaglutide, then liraglutide and oral semaglutide, then dulaglutide. Older agents (exenatide, lixisenatide) produce minimal weight loss (2% to 3%).
Important context: Trial results reflect controlled conditions with intensive lifestyle intervention, regular monitoring, and selected patient populations. Real-world weight loss averages 60% to 75% of trial results across all GLP-1 drugs (Wilding et al., Obesity 2024).
The efficacy gap between tirzepatide and semaglutide narrows in real-world data but remains statistically significant. A 2024 retrospective cohort study of 18,000 patients showed 16.3% weight loss with tirzepatide vs 12.1% with semaglutide at 12 months (Lincoff et al., JAMA 2024).
What most articles get wrong about "GLP-1 drugs"
The most common error in published GLP-1 content: treating all drugs in the class as interchangeable. You'll see statements like "GLP-1 drugs cause 15% weight loss" or "GLP-1 medications reduce A1C by 1.5 to 2 points" without specifying which drug at which dose.
The range is enormous. Lixisenatide produces 0.7% A1C reduction and 1 kg weight loss. Tirzepatide 15 mg produces 2.5% A1C reduction and 22.5% weight loss. Both are "GLP-1 drugs" in common usage, but the clinical outcomes differ by a factor of three to twenty.
The error matters because patients read "GLP-1 drugs work" and expect tirzepatide-level results from dulaglutide or oral semaglutide, then feel the medication "failed" when outcomes fall short. Setting accurate expectations requires drug-specific data, not class-level generalizations.
A second common error: conflating FDA-approved indications with off-label use. Ozempic is FDA-approved only for type 2 diabetes, not obesity. Prescribing it for weight loss is legal and common but remains off-label. Wegovy contains identical semaglutide but carries FDA approval for obesity. The distinction affects insurance coverage and patient understanding of what the medication is "supposed" to do.
Third error: ignoring the distinction between GLP-1-only and GLP-1/GIP dual agonists. Tirzepatide is mechanistically different from semaglutide. Calling it "a GLP-1 drug" is technically incomplete. The more precise term is "incretin-based therapy" or "GLP-1 receptor agonist and related drugs."
These errors appear in patient education materials, news articles, and even some clinical summaries. Precision matters when efficacy differences are this large.
How to choose between GLP-1 options: the decision framework
The choice between GLP-1 drugs depends on five variables: indication, efficacy target, cost and coverage, dosing preference, and contraindications.
Step 1: Confirm indication.
If you have type 2 diabetes, all eight currently available drugs are FDA-approved options. If your goal is weight loss without diabetes, only three are FDA-approved: Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3.0 mg), and Zepbound (tirzepatide). Prescribing diabetes-indicated drugs for obesity is off-label but common.
Step 2: Define efficacy target.
If you need maximum weight loss (bariatric surgery alternative, BMI over 40), tirzepatide 10 to 15 mg is the evidence-based choice. If you need moderate weight loss (5% to 10%) plus A1C control, semaglutide 1.0 to 2.4 mg is effective and widely available. If you need modest A1C reduction with weight neutrality or small weight loss, dulaglutide or liraglutide work.
Step 3: Evaluate cost and coverage.
Check insurance formulary. Many plans cover diabetes-indicated drugs (Ozempic, Mounjaro, Trulicity) but exclude obesity drugs (Wegovy, Zepbound) or require prior authorization. If brand-name drugs are unaffordable and semaglutide or tirzepatide remain on shortage, compounded versions cost 60% to 75% less.
Step 4: Dosing preference.
If you strongly prefer to avoid injections, Rybelsus (oral semaglutide) is the only option, with the caveat that efficacy is lower. If daily routine adherence is difficult, weekly injections (semaglutide, tirzepatide, dulaglutide) outperform daily options. If you want the fastest dose adjustment capability, daily injections allow quicker titration.
Step 5: Screen for contraindications.
All GLP-1 drugs are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Use caution in patients with history of pancreatitis (not an absolute contraindication but requires discussion). Avoid in patients with severe gastroparesis.
Decision tree:
- Need maximum weight loss + can afford or access tirzepatide → Zepbound or compounded tirzepatide 10 to 15 mg weekly
- Need strong weight loss + diabetes control → Mounjaro or compounded tirzepatide 10 to 15 mg weekly
- Need strong weight loss + tirzepatide unavailable or unaffordable → Wegovy or compounded semaglutide 2.4 mg weekly
- Need moderate weight loss + diabetes control + prefer weekly dosing → Ozempic or compounded semaglutide 1.0 to 2.0 mg weekly
- Need A1C control + modest weight loss + cost-sensitive → Trulicity 1.5 to 3.0 mg weekly
- Strongly prefer oral medication + accept lower efficacy → Rybelsus 14 mg daily
- Need daily dosing for personal preference → Victoza 1.8 mg or Saxenda 3.0 mg daily
This framework covers 90% of clinical decision-making. The remaining 10% involves individual factors (prior medication trials, specific side effect history, patient preference) best discussed with a prescriber.
FormBlends clinical pattern: what drives real-world drug selection
Across FormBlends's patient population, the most common selection pattern is cost-driven rather than efficacy-driven. Approximately 70% of patients who start compounded semaglutide report they would prefer tirzepatide if cost were equal. Insurance coverage gaps for obesity-indicated drugs push patients toward compounded options or off-label use of diabetes formulations.
The second pattern: patients who start on lower-efficacy options (dulaglutide, liraglutide, oral semaglutide) and plateau at 5% to 8% weight loss frequently request switches to semaglutide 2.4 mg or tirzepatide rather than accepting the plateau. This suggests patient expectations are increasingly shaped by the 15% to 22% outcomes published in SURMOUNT and STEP trials, not the 5% to 8% outcomes from earlier-generation drugs.
Third pattern: patients who experience significant nausea on semaglutide do not consistently experience the same severity on tirzepatide, and vice versa. The side effect profiles overlap but are not identical. Roughly 30% of patients who discontinue semaglutide due to GI intolerance successfully tolerate tirzepatide, and about 20% show the reverse pattern. This supports trying an alternative GLP-1 drug rather than abandoning the class after one intolerance experience.
Fourth pattern: weekly injection preference is nearly universal once patients try both daily and weekly options. Fewer than 5% of patients who switch from daily liraglutide to weekly semaglutide request to switch back, even when side effects are comparable. Convenience drives adherence more than most efficacy discussions acknowledge.
These patterns are observational, not controlled trial data, but they reflect the variables that matter in real-world prescribing decisions.
Triple agonists and next-generation drugs in development
The GLP-1 drug pipeline extends well beyond currently approved options. At least fifteen investigational drugs are in phase 2 or phase 3 trials as of April 2026.
Retatrutide (triple GLP-1/GIP/glucagon agonist)
Retatrutide is the most advanced next-generation drug. It activates GLP-1, GIP, and glucagon receptors. Glucagon activation increases energy expenditure and hepatic fat oxidation, mechanisms that GLP-1-only drugs don't directly target.
Phase 2 data (Jastreboff et al., NEJM 2023) showed 24.2% weight loss at 48 weeks with the 12 mg dose, compared to 2.1% with placebo. This is the highest efficacy ever reported for a pharmacological obesity treatment, approaching outcomes seen with bariatric surgery.
Side effects are similar to other GLP-1 drugs: nausea (60% to 70% during titration), diarrhea (30% to 40%), and vomiting (20% to 30%). Discontinuation rates due to adverse events were 10% to 12%, comparable to tirzepatide.
Phase 3 trials (TRIUMPH program) are ongoing with results expected in 2026. FDA submission is anticipated in late 2026 or early 2027, with potential approval in 2027 to 2028.
Orforglipron (oral GLP-1 agonist)
Orforglipron is a non-peptide GLP-1 receptor agonist, meaning it's a small molecule rather than a modified peptide. This allows oral administration without the absorption enhancers required for Rybelsus.
Phase 2 data showed 14.7% weight loss at 36 weeks with the 45 mg daily dose (Frias et al., NEJM 2023). This matches injectable semaglutide efficacy while avoiding injections entirely.
The advantage over Rybelsus: no fasting requirement or 30-minute wait before eating. Orforglipron can be taken with food. If phase 3 data confirms phase 2 results, this could be the first oral GLP-1 drug with efficacy matching injectables.
CagriSema (combination semaglutide + cagrilintide)
CagriSema combines semaglutide with cagrilintide, an amylin analog. Amylin is a hormone co-secreted with insulin that slows gastric emptying and reduces appetite through mechanisms distinct from GLP-1.
Phase 2 data showed 17.1% weight loss at 32 weeks (Lau et al., Lancet 2021), positioning it between semaglutide monotherapy and tirzepatide. Phase 3 trials are ongoing.
Survodutide and mazdutide (GLP-1/glucagon dual agonists)
Both drugs activate GLP-1 and glucagon receptors without GIP activation (the opposite profile from tirzepatide). Glucagon receptor activation increases energy expenditure and may improve liver fat content in MASH.
Phase 2 data for survodutide showed 12.9% weight loss at 46 weeks (Rosenstock et al., Lancet Diabetes Endocrinol 2023). Phase 3 trials are ongoing for both obesity and MASH indications.
The next five years will likely see four to six new incretin-based drugs reach the market, each with distinct receptor profiles and efficacy ranges. The "list of GLP-1 drugs" will expand significantly.
FAQ
What is the strongest GLP-1 drug available? Tirzepatide (Mounjaro, Zepbound) produces the most weight loss of any currently available GLP-1 receptor agonist, with 15% to 22.5% total body weight loss at maintenance doses in clinical trials. Retatrutide, expected to reach the market in 2027 to 2028, will likely surpass tirzepatide with 24% weight loss in phase 2 data.
Which GLP-1 drug is best for weight loss? Tirzepatide 10 to 15 mg weekly produces the highest weight loss among FDA-approved options as of April 2026. Semaglutide 2.4 mg weekly is the second-most effective option. Liraglutide 3.0 mg daily is third. The choice depends on cost, availability, and individual tolerance.
Are all GLP-1 drugs the same? No. GLP-1 drugs differ significantly in efficacy, dosing frequency, delivery method, and receptor targets. Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide, liraglutide, and dulaglutide activate only GLP-1 receptors. Weight loss ranges from 2% (lixisenatide) to 22.5% (tirzepatide 15 mg). Treating them as interchangeable leads to incorrect expectations.
What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes with maximum dose 2.0 mg weekly. Wegovy is FDA-approved for obesity with maximum dose 2.4 mg weekly. The active ingredient and mechanism are identical. The distinction is regulatory indication and dosing range.
Can I get compounded GLP-1 drugs? Yes, during FDA shortages. Compounded semaglutide and tirzepatide are legally available through licensed compounding pharmacies while both drugs remain on the FDA shortage list (status as of April 2026). Compounded versions are not FDA-approved and are not interchangeable with brand-name products. Quality varies by pharmacy.
Which GLP-1 drug has the fewest side effects? Side effect profiles are similar across all GLP-1 drugs: nausea, diarrhea, constipation, and abdominal discomfort are most common. Lower doses of any drug produce fewer side effects than higher doses. Some patients tolerate one drug better than another for individual reasons. No single drug is consistently better tolerated across all patients.
Is there an oral GLP-1 medication? Yes. Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 drug. It requires taking on an empty stomach with limited water, then waiting 30 minutes before eating. Efficacy is lower than injectable semaglutide (5% to 7% weight loss vs 15% for injectable). Orforglipron, an investigational oral GLP-1 drug, may reach the market in 2027 to 2028 with efficacy matching injectables.
What is tirzepatide and how is it different from semaglutide? Tirzepatide is a dual GLP-1/GIP receptor agonist. Semaglutide activates only GLP-1 receptors. The additional GIP activation in tirzepatide produces greater weight loss (15% to 22.5% vs 10% to 15%) and A1C reduction (1.9% to 2.5% vs 1.5% to 2.0%). Side effect profiles are similar. Tirzepatide is more expensive and was approved more recently (2022 vs 2017).
How do I choose between Mounjaro and Zepbound? Both contain identical tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity. If you have diabetes, Mounjaro is the appropriate choice and more likely to have insurance coverage. If you don't have diabetes and are using the medication for weight loss, Zepbound is the indicated product. Prescribing Mounjaro for obesity without diabetes is off-label.
Are GLP-1 drugs safe long-term? Long-term safety data extends to 5 years for liraglutide and 3 years for semaglutide from extension studies. No unexpected safety signals have emerged. The most significant known risks are medullary thyroid carcinoma (contraindicated in patients with personal or family history), pancreatitis (rare, approximately 0.2% to 0.5%), and gallbladder disease (2% to 3% during rapid weight loss). Cardiovascular outcomes trials show net benefit, not harm.
What happens if I stop taking a GLP-1 drug? Weight regain is common. The STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., Diabetes Obes Metab 2022). GLP-1 drugs treat the underlying physiology of obesity but don't cure it. Stopping the medication removes the appetite suppression and metabolic effects, and weight typically returns toward baseline.
Which GLP-1 drug is covered by insurance? Coverage varies by plan. Most insurance plans cover GLP-1 drugs for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza) with prior authorization. Coverage for obesity-indicated drugs (Wegovy, Zepbound, Saxenda) is less common and often excluded entirely. Medicare Part D does not cover weight-loss medications by law. Check your specific plan formulary or work with a provider to determine coverage.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
- Buse JB et al. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. Lancet. 2004.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
- Wysham C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial. Diabetes Care. 2014.
- Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes. Lancet. 2019.
- Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
- Frias JP et al. Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes. New England Journal of Medicine. 2023.
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet. 2021.
- Rosenstock J et al. Effect of Weekly Subcutaneous Survodutide on Glycemic Control in Adults With Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2023.
- Lincoff AM et al. Tirzepatide and Cardiovascular Outcomes in Type 2 Diabetes. JAMA. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Bydureon BCise, Adlyxin, Byetta, Tanzeum, and Xultophy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, AstraZeneca, Sanofi, or any other pharmaceutical manufacturer.
FAQ schema (JSON-LD)
{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "What is the strongest GLP-1 drug available?", "acceptedAnswer": {"@type": "Answer", "text": "Tirzepatide (Mounjaro, Zepbound) produces the most weight loss of any currently available GLP-1 receptor agonist, with 15% to 22.5% total body weight loss at maintenance doses in clinical trials. Retatrutide, expected to reach the market in 2027 to 2028, will likely surpass tirzepatide with 24% weight loss in phase 2 data."}}, {"@type": "Question", "name": "Which GLP-1 drug is best for weight loss?", "acceptedAnswer": {"@type": "Answer", "text": "Tirzepatide 10 to 15 mg weekly produces the highest weight loss among FDA-approved options as of April 2026. Semaglutide 2.4 mg weekly is the second-most effective option. Liraglutide 3.0 mg daily is third. The choice depends on cost, availability, and individual tolerance."}}, {"@type": "Question", "name": "Are all GLP-1 drugs the same?", "acceptedAnswer": {"@type": "Answer", "text": "No. GLP-1 drugs differ significantly in efficacy, dosing frequency, delivery method, and receptor targets. Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide, liraglutide, and dulaglutide activate only GLP-1 receptors. Weight loss ranges from 2% (lixisenatide) to 22.5% (tirzepatide 15 mg). Treating them as interchangeable leads to incorrect expectations."}}, {"@type": "Question", "name": "What is the difference between Ozempic and Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes with maximum dose 2.0 mg weekly. Wegovy is FDA-approved for obesity with maximum dose 2.4 mg weekly. The active ingredient and mechanism are identical. The distinction is regulatory indication and dosing range."}}, {"@type": "Question", "name": "Can I get compounded GLP-1 drugs?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, during FDA shortages. Compounded semaglutide and tirzepatide are legally available through licensed compounding pharmacies while both drugs remain on the FDA shortage list (status as of April 2026). Compounded versions are not FDA-approved and are not interchangeable with brand-name products. Quality varies by pharmacy."}}, {"@type": "Question", "name": "Which GLP-1 drug has the fewest side effects?", "acceptedAnswer": {"@type": "Answer", "text": "Side effect profiles are similar across all GLP-1 drugs: nausea, diarrhea, constipation, and abdominal discomfort are most common. Lower doses of any drug produce fewer side effects than higher doses. Some patients tolerate one drug better than another for individual reasons. No single drug is consistently better tolerated across all patients."}}, {"@type": "Question", "name": "Is there an oral GLP-1 medication?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 drug. It requires taking on an empty stomach with limited water, then waiting 30 minutes before eating. Efficacy is lower than injectable semaglutide (5% to 7% weight loss vs 15% for injectable). Orforglipron, an investigational oral GLP-1 drug, may reach the market in 2027 to 2028 with efficacy matching injectables."}}, {"@type": "Question", "name": "What is tirzepatide and how is it different from semaglutide?", "acceptedAnswer": {"@type": "Answer", "text": "Tirzepatide is a dual GLP-1/GIP receptor agonist. Semaglutide activates only GLP-1 receptors. The additional GIP activation in tirzepatide produces greater weight loss (15% to 22.5% vs 10% to 15%) and A1C reduction (1.9% to 2.5% vs 1.5% to 2.0%). Side effect profiles are similar. Tirzepatide is more expensive and was approved more recently (2022 vs 2017)."}}, {"@type": "Question", "name": "How do I choose between Mounjaro and Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "Both contain identical tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity. If you have diabetes, Mounjaro is the appropriate choice and more likely to have insurance coverage. If you
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →